A Subject-, Investigator-, and Sponsor-blinded, Randomized, Placebo-controlled, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2018
At a glance
- Drugs VAY 736 (Primary)
- Indications Multiple sclerosis; Pemphigus vulgaris; Rheumatoid arthritis; Sjogren's syndrome
- Focus Pharmacodynamics
- Sponsors Novartis Pharmaceuticals
- 25 Mar 2018 Planned End Date changed from 29 Jul 2022 to 6 Apr 2022.
- 25 Mar 2018 Planned primary completion date changed from 29 Jul 2022 to 6 Apr 2022.
- 25 Mar 2018 Status changed from not yet recruiting to recruiting.